Changzhou Sunlight Pharmaceutical Co., Ltd. (SunlightPharma) plans to invest RMB500 million in the construction of an integrated production, research and development base for high-end polymide pharmaceutical intermediates in Changxing Island of Dalian. 

   The project will be located in Fine Chemical Innovation Park of Changxing Island and be built up in two phases. Products will be applied in the fields of national defense and military industry, aerospace, electronic information and biomedical etc, mainly serving international customers from Europe, the US, Japan and South Korea etc.